KDR and neoplasm: In addition, like ramucirumab against vascular endothelial growth factor receptor 2 (VEGFR2) [37] and trastuzumab against HER2 [38], Lic5 demonstrates its anti-cancer effect by acting on the upstream component of signaling pathway essential to tumor progression.